एमक्युअर फार्मास्युटिकल्स शेअर किंमत

Consolidated revenue from operations during the quarter stood at 2,580.45 crore as against 2,100.54 कोटी वर्ष-पूर्व कालावधीत

• बिझनेस लाईन
• 21 मिनिटे 7 सेकंदांपूर्वी

<h3><span style="font-size:16px;"><strong>फार्मास्युटिकल्स कंपनी एम्क्युअर फार्मास्युटिकल्सने Q1FY27 परिणामांची घोषणा केली</strong></span></h3><p><strong _ngcontent-ng-c1006311636="">एकत्रित फायनान्शियल हायलाईट्स:</strong></p><ul><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Revenue from Operations:</strong> The company reported revenue of Rs 25,804.47 million in Q1FY27, representing a growth of 22.84% compared to Rs 21,005.37 million in Q1FY26 (YoY) and an increase of 4.48% from Rs 24,697.03 million in Q4FY26 (QoQ).</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Total Income:</strong> Total income for the quarter stood at Rs 25,825.18 million, up 22.73% YoY from Rs 21,042.33 million and up 4.40% QoQ from Rs 24,736.95 million.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">EBITDA:</strong> Consolidated EBITDA stood at Rs 5,080 million in Q1FY27, registering a growth of 25.80% YoY from Rs 4,039 million and a growth of 4.63% QoQ from Rs 4,855 million.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">EBITDA Margin:</strong> The EBITDA margin improved to 19.7% in Q1FY27 compared to 19.2% in Q1FY26 and remained stable at 19.7% compared to Q4FY26.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Profit Before Tax (PBT):</strong> PBT (before exceptional items) was Rs 3,935.26 million in Q1FY27, an increase of 33.74% from Rs 2,942.58 million in Q1FY26 and up 18.93% from Rs 3,308.75 million in Q4FY26.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Net Profit:</strong> Net profit for the period reached Rs 2,924.93 million in Q1FY27, reflecting a growth of 36.17% YoY from Rs 2,147.93 million and a 20.00% increase QoQ from Rs 2,437.36 million.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Earnings Per Share (EPS):</strong> Basic and Diluted EPS stood at Rs 15.50 for Q1FY27, compared to Rs 10.92 in Q1FY26 and Rs 12.84 in Q4FY26.</li></ul><p><strong _ngcontent-ng-c1006311636="">स्टँडअलोन फायनान्शियल हायलाईट्स:</strong></p><ul><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Revenue from Operations:</strong> Standalone revenue for Q1FY27 was Rs 14,509.31 million, a growth of 32.31% YoY from Rs 10,965.73 million and a marginal decline of 1.14% QoQ from Rs 14,677.03 million.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Total Income:</strong> Total standalone income stood at Rs 14,759.63 million in Q1FY27, up 32.01% YoY from Rs 11,180.97 million.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Net Profit:</strong> Standalone PAT reached Rs 2,001.08 million in Q1FY27, representing a YoY growth of 63.0% from Rs 1,227.89 million and a QoQ decline of 14.37% from Rs 2,336.97 million.</li></ul><p><strong _ngcontent-ng-c1006311636="">बिझनेस हायलाईट्स</strong></p><ul><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Segment Performance:</strong> The group operates primarily in a single reportable segment, "Pharmaceuticals".</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Domestic Business:</strong> Revenue from the domestic market grew by 10.2% YoY to Rs 10,953 million, accounting for 42.4% of consolidated revenue. Growth was driven by brands in CNS, cardiology, and the women’s health franchise.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">आंतरराष्ट्रीय बिझनेस:</strong> International sales stood at Rs 14,851 million, showing a robust growth of 34.2% YoY and contributing 57.6% to consolidated revenue.<ul><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Europe:</strong> Grew by 32.8% YoY to Rs 5,367 million.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Canada:</strong> Grew by 24.6% YoY to Rs 4,266 million.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Rest of World (RoW):</strong> Grew by 44.8% YoY to Rs 5,218 million, led by ARV performance.</li></ul></li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Research & Development:</strong> R&D investment stood at Rs 904 million, representing 3.5% of the total revenue for the quarter.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">ऑपरेशनल अपडेट्स:</strong><ul><li _ngcontent-ng-c1006311636="">Acquired 100% of Cutimed Inc. in Canada effective April 1, 2026, to strengthen the dermatology and cosmetic portfolio.</li><li _ngcontent-ng-c1006311636="">Acquired the remaining minority stake in Gennova Biopharmaceuticals, making it a wholly-owned subsidiary effective July 21, 2026.</li><li _ngcontent-ng-c1006311636="">Gennova executed a Business Transfer Agreement (BTA) for the slump sale of its mRNA business for Rs 1,395 million on July 10, 2026.</li></ul></li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Leadership Changes:</strong> Mr. Berjis Desai will retire as Chairman. Post the upcoming AGM, Mr. Satish Mehta will take over as Chairman in addition to his role as Managing Director and CEO. Mr. Samit Mehta has been appointed as the Chief Operating Officer of Emcure and CEO of Gennova.</li><li><strong _ngcontent-ng-c1006311636="">मॅनेजमेंट कॉमेंटरी (व्हर्बेटिम)</strong></li></ul><p _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Satish Mehta, Managing Director and CEO, Emcure Pharmaceuticals, said: </strong>"We have begun FY27, the second year of our five-year plan—on a strong footing. FY26 was about putting the building blocks in place across teams, portfolio, integration and operating discipline. FY27 is about delivery, and Q1 is an encouraging early signal.</p><p _ngcontent-ng-c1006311636="">Revenue grew 22.8% year-on-year to Rs 25,804 million and was supported by momentum across geographies. EBITDA grew 25.8% to Rs 5,080 million with margin improving to 19.7%, up ~50 basis points year-on-year, reflecting productivity gains and operating leverage. PAT grew faster at 36.2% to Rs 2,925 million, underlining the strength of the quarter's operating performance."</p><p><a class="lb" href="/marathi/get-document/post/pdf/5768643/" target="_blank">रिझल्ट PDF</a></p>

• ट्रेंडलाईन
• 1 तास 21 मिनिटांपूर्वी

Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 - Change in composition of the Board of the Company

• बीएसई इंडिया
• 1 तास 42 मिनिटांपूर्वी